KROS Keros Therapeutics, Inc.companySEC Filings & Insider Trading Activity 2026
Latest Keros Therapeutics, Inc. (KROS) SEC EDGAR filings in 2026 — including the most recent 10-K annual report filed on March 4, 2026, a 10-Q quarterly report filed on November 5, 2025, an 8-K current report filed on March 9, 2026. SignalX aggregates every new 10-K annual report, 10-Q quarterly report, 8-K current report, and Form 4 insider transaction for Keros Therapeutics, Inc. (KROS) (SEC CIK 1664710), with AI-powered section-by-section summaries updated daily.
Latest 2026 SEC Filing Dates
AI 8-K Current Report AnalysisRecent 8-K Filings
Item 8.01: Other Events
- • Keros partnering with Mass General Hospital to design Phase 2 trial of rinvatercept in ALS patients via HEALEY ALS MyMatch platform
- • HEALEY MyMatch is a prestigious adaptive trial platform — entry signals clinical validation and accelerates path to data vs. standalone trial design
Item 2.02: Results of Operations and Financial Condition
- • Q4 and full-year 2025 financial results disclosed via press release (Exhibit 99.1)
- • Includes "recent business highlights" — likely pipeline or clinical updates material to this clinical-stage biotech
Item 7.01: Regulation FD Disclosure
- • Updated investor presentation filed March 4, 2026 — signals potential catalysts or strategic updates worth reviewing in Exhibit 99.1
- • Furnished (not filed) under Reg FD — limits legal liability but ensures broad, simultaneous investor access to material information
Recent 8-K FilingsCurrent Reports
AI-powered analysis of Keros Therapeutics, Inc. (KROS) 8-K current reports disclosing material events.
Latest 2026 SEC Filings — 10-K, 10-Q, 8-K & Form 4
| Form | Filing Date | Period | Analysis | SEC |
|---|---|---|---|---|
8-K | Mar 9, 2026 | — | Analysis | — |
8-K | Mar 4, 2026 | — | Analysis | — |
10-K | Mar 4, 2026 | Dec 31, 2025 | — | |
8-K | Mar 4, 2026 | — | Analysis | — |
8-K | Feb 26, 2026 | — | Analysis | — |
8-K | Feb 18, 2026 | — | — | |
8-K | Jan 9, 2026 | — | — | |
10-Q | Nov 5, 2025 | Sep 30, 2025 | — | |
10-Q | Aug 6, 2025 | Jun 30, 2025 | — | |
10-Q | May 6, 2025 | Mar 31, 2025 | — | |
10-K | Feb 26, 2025 | Dec 31, 2024 | — | |
10-Q | Nov 6, 2024 | Sep 30, 2024 | — | |
10-Q | Aug 7, 2024 | Jun 30, 2024 | — | |
10-Q | May 8, 2024 | Mar 31, 2024 | — | |
10-K | Feb 28, 2024 | Dec 31, 2023 | — | |
10-Q | Nov 6, 2023 | Sep 30, 2023 | — | |
10-Q | Aug 7, 2023 | Jun 30, 2023 | — | |
10-Q | May 4, 2023 | Mar 31, 2023 | — | |
10-K | Mar 3, 2023 | Dec 31, 2022 | — | |
10-Q | Nov 3, 2022 | Sep 30, 2022 | — | |
10-Q | Aug 4, 2022 | Jun 30, 2022 | — | |
10-Q | May 5, 2022 | Mar 31, 2022 | — | |
10-K | Mar 9, 2022 | Dec 31, 2021 | — | |
10-Q | Nov 4, 2021 | Sep 30, 2021 | — | |
10-Q | Aug 5, 2021 | Jun 30, 2021 | — |
Frequently Asked Questions
What are the latest KROS SEC filings in 2026?
Keros Therapeutics, Inc. (KROS) has filed a 10-K annual report on March 4, 2026, a 10-Q quarterly report on November 5, 2025, an 8-K current report on March 9, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.
When did KROS file its most recent 10-K annual report?
Keros Therapeutics, Inc. (KROS) filed its most recent 10-K annual report on March 4, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.
How do I view KROS 10-Q quarterly reports?
Keros Therapeutics, Inc. (KROS)'s most recent 10-Q quarterly report was filed on November 5, 2025. SignalX displays every KROS 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.
What 8-K current reports has KROS filed recently?
Keros Therapeutics, Inc. (KROS)'s most recent 8-K was filed on March 9, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.
Where can I find KROS insider trading activity (Form 4)?
SignalX aggregates every KROS Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.
How often does KROS file with the SEC?
Keros Therapeutics, Inc. (KROS) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new KROS filing with AI-powered analysis.
What is the difference between 10-K, 10-Q, and 8-K SEC filings?
A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Keros Therapeutics, Inc. (KROS).
What is KROS's SEC CIK number?
Keros Therapeutics, Inc. (KROS)'s SEC CIK (Central Index Key) number is 1664710. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1664710 to look up all KROS filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.
Where can I find KROS return on equity (ROE) and financial data?
SignalX extracts XBRL financial data from Keros Therapeutics, Inc. (KROS) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.
Stay on top of Keros Therapeutics, Inc. SEC filings
Insider trading data, fund holdings, cross-signal detection, and AI-powered analysis for 30+ filings.